DGAP-Adhoc: MOLOGEN announces top-line data of IMPALA study

Publication of an insider information pursuant to Section 17 of the regulation (EU) No. 596/2014

MOLOGEN announces top-line data of IMPALA study

Berlin, 5 August 2019 - Today, the biopharmaceutical company MOLOGEN AG (ISIN DE000A2LQ900, SIN A2L Q90) announced the top line data of its pivotal phase III IMPALA study. The study compares the TLR9 agonist lefitolimod (MGN1703) with local standard of care as a maintenance therapy in patients with metastatic colorectal cancer presenting with an objective tumor response following first-line induction therapy. The primary endpoint - overall survival (OS) - was not met in this trial comparing single agent lefitolimod with standard of care maintenance treatment. Also, in various pre-defined subgroups, no survival benefit could be shown. No new safety signals were detected.

In light of these results the future strategy of MOLOGEN will focus on combination approaches for both lefitolimod and the first clinical candidate from the EnanDIM^(R) family in ongoing and planned clinical trials. This strategy serves as cornerstone for ongoing licensing and funding efforts.

The detailed data from this first top-line analysis of the IMPALA trial will be submitted for presentation at an upcoming international scientific congress.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 37
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.